  Management of children with newly diagnosed immune thrombocytopenia<symptom> ( ITP) consists of careful observation or immunomodulatory treatment. Observational studies suggest a lower risk of chronic ITP in children after intravenous immunoglobulin ( IVIg) treatment. In this multicenter randomized trial , children aged 3 months-16 years with newly diagnosed ITP , platelet counts ≤ 20 × 10